Nemolizumab Update: Galderma’s IL-31 Blocker Continues to Wow in PN, AD
More than 80% of nemolizumab-treated patients with prurigo nodularis (PN) experienced improvement in itch, and more than 60% achieved clear or almost-clear skin, according to one-year data from an interim analysis of the OLYMPIA long-term extension (LTE) study presented at the 2024 American Academy of Dermatology Association (AAD) Annual meeting in San Diego. In addition, […]